Dr Simon Pacey

Cambridge University Hospitals NHS Foundation Trust
University of Cambridge
Department of Oncology

Position: Academic Consultant in Medical Oncology
Personal home page: http://www.oncology.cam.ac.uk/
Email:   simonpacey@medschl.cam.ac.uk

PubMed journal articles - click here

Dr Simon Pacey is pleased to consider applications from prospective PhD students.

Research description

My research interests are: Early phase clinical trials (phase I/II) and Urological malignancy (prostate cancers). My research is centered around the transition of new drugs into humans and exploring and proposing new treatments paradigms for men with early/ localised prostate cancer
Current projects include:
- Chief Investigator Cambridge Neoadjuvant Carcinoma of the Prostate (CANCAP) studies: Clinical studies of investigational drugs prior to radical prostatectomy,  clinicatrials.gov identifiers NCT02064608 (AZD2014), see GU ASCO 2017 and NCT02324998 (Olaparib)
- Pre-clinical studies to investigate effect of mTOR inhibition in early, hormone sensitive prostate cancer
- Phase 1/ early phase trials in patients with advanced solid tumours (local investigator led, Cancer Research UK and industry collaborations both as CI and PI)

Research Programme
Urological Malignancies
Methods and technologies
Clinical practice
Clinical trials
Tumour type interests
Bladder
Lung
Prostate
scp46
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge


Key publications

Wan JC, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017 Apr;17(4):223-238

Kumar SS & Pacey S. The role of chemotherapy and new targeted agents in the management of primary prostate cancer. Journal of Clinical Urology
2017, Vol. 9(2S) 30–37

Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015 Sep;16(9):e447-59.

Lee CP, Taylor NJ, Attard G, Pacey S, Nathan PD, de Bono JS, Temple G, Bell S, Stefanic M, Stopfer P, Tang A, Koh DM, Collins DJ, d'Arcy J, Padhani AR, Leach MO, Judson IR, Rustin GJ. Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors. Oncologist. 2015 Apr;20(4):368-9.

Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarin E, Meresse V, Soria JC. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clin Cancer Res. 2014 Aug 15;20(16):4251-61.

Powles T, Foreshew SJ, Shamash J, Sarwar N, Crabb S, Sahdev A, Nixon J, Lim L, Pungaliya A, Foreshaw A, Davies R, Greenwood M, Wilson P, Pacey S, Galazi M, Jones R, Chowdhury S. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. Eur J Cancer. 2014 Aug;50(12):2057-64.

Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I. 2011. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res. 17(6):1561-70

Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, Judson I, Workman P, Eisen T. 2012 A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs. 30(1):341-9

Pacey S, Ratain MJ, Flaherty KT, Kaye SB, Cupit L, Rowinsky EK, Xia C, O'Dwyer PJ, Judson IR. 2011. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drugs. 29(3):481-8.